EV-Based Liquid Biopsy and 3D Cancer Models for Precision Oncology

I offer integrated expertise in extracellular vesicle (EV) isolation, characterization, lipidomic profiling, and functional assessment using biochemical, imaging, flow-cytometric, and lipidomics-based approaches. My group develops and applies 3D cancer models, including spheroids and patient-derived organoids, to study EV-mediated tumour communication, biomarker discovery, tumour–microenvironment interactions, and EV uptake/penetration mechanisms.

We have access to clinical samples and established workflows for EV profiling, lipidomics, membrane-associated lipid signatures, and mechanistic validation assays, with a current clinical focus on bladder cancer and complementary expertise in breast cancer models.

I am particularly interested in joining already forming Horizon Europe Cancer Mission consortia as a partner or work-package contributor, especially in projects focusing on translational biomarker development, liquid biopsy, precision oncology, and clinically relevant omics integration. My group could contribute EV/lipidomic biomarker validation, functional cancer models, liquid-biopsy assay development, and integration of EV-based readouts with clinical and multi-omics datasets. I would also be interested in collaborating with teams working on AI-assisted omics analysis, EV-based diagnostics, microbiome–host interactions, or computational integration of multi-layer clinical data.